Carl G Figdor (C G Figdor)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Topics

Dendritic Cells

Top Venues

Nature communications

Journal for immunotherapy of cancer

Cancer immunology, immunotherapy : CII

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

This page only lists publications with an associated author ORCID identifier.

Publications

Kalijn F Bol, Ghaith Bakdash, Martine Bloemendal, Wouter W van Willigen, Simone Hins-de Bree, Anna L de Goede, Annemiek J de Boer, Kevin J H Bos, Tjitske Duiveman-de Boer, Michel A M Olde Nordkamp, Tom G M van Oorschot, Carlijn J Popelier, Jeanne M Pots, Nicole M Scharenborg, Mandy W M M van de Rakt, Valeska de Ruiter, Wilmy S van Meeteren, Michelle M van Rossum, Sandra J Croockewit, Bouke J Koeneman, Jeroen H A Creemers, Inge M N Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A van der Veldt, Dirk J van Grünhagen, Johanna E M Werner, Johannes J Bonenkamp, John B A G Haanen, Marye J Boers-Sonderen, Rutger H T Koornstra, Martijn F Boomsma, Erik H J Aarntzen, Martin Gotthardt, James Nagarajah, Theo J M de Witte, Carl G Figdor, Johannes H W de Wilt, Johannes C Textor, Jan Willem B de Groot, Winald R Gerritsen, Ingrid Jolanda M De Vries
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. Nature communications 15 (1) (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Kalijn F Bol, Ghaith Bakdash, Martine Bloemendal, Wouter W van Willigen, Simone Hins-de Bree, Anna L de Goede, Annemiek J de Boer, Kevin J H Bos, Tjitske Duiveman-de Boer, Michel A M Olde Nordkamp, Tom G M van Oorschot, Carlijn J Popelier, Jeanne M Pots, Nicole M Scharenborg, Mandy W M M van de Rakt, Valeska de Ruiter, Wilmy S van Meeteren, Michelle M van Rossum, Sandra J Croockewit, Bouke J Koeneman, Jeroen H A Creemers, Inge M N Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A van der Veldt, Dirk J van Grünhagen, Johanna E M Werner, Johannes J Bonenkamp, John B A G Haanen, Marye J Boers-Sonderen, Rutger H T Koornstra, Martijn F Boomsma, Erik H J Aarntzen, Martin Gotthardt, James Nagarajah, Theo J M de Witte, Carl G Figdor, Johannes H W de Wilt, Johannes C Textor, Jan Willem B de Groot, Winald R Gerritsen, Ingrid Jolanda M De Vries
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. Nature communications 15 (1) (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Kalijn F Bol, Ghaith Bakdash, Martine Bloemendal, Wouter W van Willigen, Simone Hins-de Bree, Anna L de Goede, Annemiek J de Boer, Kevin J H Bos, Tjitske Duiveman-de Boer, Michel A M Olde Nordkamp, Tom G M van Oorschot, Carlijn J Popelier, Jeanne M Pots, Nicole M Scharenborg, Mandy W M M van de Rakt, Valeska de Ruiter, Wilmy S van Meeteren, Michelle M van Rossum, Sandra J Croockewit, Bouke J Koeneman, Jeroen H A Creemers, Inge M N Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A van der Veldt, Dirk J van Grünhagen, Johanna E M Werner, Johannes J Bonenkamp, John B A G Haanen, Marye J Boers-Sonderen, Rutger H T Koornstra, Martijn F Boomsma, Erik H J Aarntzen, Martin Gotthardt, James Nagarajah, Theo J M de Witte, Carl G Figdor, Johannes H W de Wilt, Johannes C Textor, Jan Willem B de Groot, Winald R Gerritsen, Ingrid Jolanda M De Vries
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. Nature communications 15 (1) (2024)
Jeroen H A Creemers, Ankur Ankan, Kit C B Roes, Gijs Schröder, Niven Mehra, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nature communications 14 (1) (2023)
Jeroen H A Creemers, Ankur Ankan, Kit C B Roes, Gijs Schröder, Niven Mehra, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nature communications 14 (1) (2023)
Jeroen H A Creemers, Ankur Ankan, Kit C B Roes, Gijs Schröder, Niven Mehra, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nature communications 14 (1) (2023)
Jeroen H A Creemers, Ankur Ankan, Kit C B Roes, Gijs Schröder, Niven Mehra, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nature communications 14 (1) (2023)
Jeroen H A Creemers, Ankur Ankan, Kit C B Roes, Gijs Schröder, Niven Mehra, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nature communications 14 (1) (2023)
Mark A J Gorris, Lieke L van der Woude, Leonie I Kroeze, Kalijn Fredrike Bol, Kiek Verrijp, Avital L Amir, Jelena Meek, Johannes C Textor, Carl G Figdor, Ingrid Jolanda M De Vries
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. Journal for immunotherapy of cancer 10 (5) (2022)
Lieke L van der Woude, Mark A J Gorris, Inge M N Wortel, Jeroen H A Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grünberg, Michel M van den Heuvel, Johannes C Textor, Carl G Figdor, Berber Piet, Willemijn S M E Theelen, Ingrid Jolanda M De Vries
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. Journal for immunotherapy of cancer 10 (10) (2022)
Camille Le Gall, Anna Cammarata, Lukas de Haas, Iván Ramos-Tomillero, Jorge Cuenca-Escalona, Kayleigh Schouren, Zacharias Wijfjes, Anouk M D Becker, Johanna Bödder, Yusuf Dölen, Ingrid Jolanda M De Vries, Carl G Figdor, Georgina Flórez-Grau, Martijn Verdoes
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion. Journal for immunotherapy of cancer 10 (4) (2022)
Jeroen H A Creemers, Willem Joost Lesterhuis, Niven Mehra, Winald R Gerritsen, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. Journal for immunotherapy of cancer 9 (5) (2022)
Giorgia Chiodin, Joel D Allen, Dean J Bryant, Philip Rock, Enrica Antonia Martino, Beatriz Valle-Argos, Patrick J Duriez, Yasunori Watanabe, Isla Henderson, James S Blachly, Katy J McCann, Jonathan C Strefford, Graham Packham, Teunis B H Geijtenbeek, Carl G Figdor, George W Wright, Louis M Staudt, W Richard Burack, Thomas A Bowden, Max Crispin, Freda K Stevenson, Francesco Forconi
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood 138 (17) (2021)
Bettina Weigelin, Annemieke Th den Boer, Esther Wagena, Kelly Broen, Harry Dolstra, Rob J De Boer, Carl G Figdor, Johannes Textor, Peter Friedl
Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nature communications 12 (1) (2021)
Steve Boudewijns, Martine Bloemendal, Nienke de Haas, Harm Westdorp, Kalijn Fredrike Bol, Ghaith Bakdash, Erik H J G Aarntzen, Willem Joost Lesterhuis, Mark A J Gorris, Alexandra Croockewit, Lieke L van der Woude, Michelle M van Rossum, Marieke Welzen, Anna de Goede, Stanleyson V Hato, Winette T A van der Graaf, Cornelis J A Punt, Rutger H T Koornstra, Winald R Gerritsen, Carl G Figdor, Ingrid Jolanda M De Vries
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer immunology, immunotherapy : CII 69 (3) (2020)
S Di Blasio, G F van Wigcheren, Anouk M D Becker, Anne van Duffelen, Mark A J Gorris, K Verrijp, Irene Stefanini, Gert-Jan Bakker, M Bloemendal, A Halilovic, A Vasaturo, G Bakdash, S V Hato, Johannes H W de Wilt, J Schalkwijk, Ingrid Jolanda M De Vries, Johannes C Textor, E H van den Bogaard, Marcella Tazzari, Carl G Figdor
The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nature communications 11 (1) (2020)
Edyta Swider, Alexander H J Staal, N Koen van Riessen, Linsey Jacobs, Paul B White, Remco Fokkink, Geert-Jan Janssen, Eric van Dinther, Carl G Figdor, Ingrid Jolanda M De Vries, Olga Koshkina, Mangala Srinivas
Design of triphasic poly(lactic- co -glycolic acid) nanoparticles containing a perfluorocarbon phase for biomedical applications. RSC advances 8 (12) (2018)
Martine Bloemendal, Mark J A Rietveld, W W van Willigen, W R Gerritsen, Carl G Figdor, Johannes J Bonenkamp, Harm Westdorp, Steve Boudewijns, Rutger H T Koornstra, Eddy M M Adang, Ghaith Bakdash, Petronella B Ottevanger, Ingrid Jolanda M De Vries, Kalijn Fredrike Bol
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 21 (6) (2018)